Exposure-efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC)

被引：0
|
作者：
Wang, Bei
Jin, Jin
Wada, Russell
Fang, Liang
Lu, Dan
Guardino, Ellie
Swain, Sandra M.
Untch, Michael
Girish, Sandhya
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Quantitat Solut, Menlo Pk, CA USA
[3] Medstar Washington Hosp Ctr, Washington, DC USA
[4] HELIOS Hosp Berlin Buch, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
644
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
    Molinelli, Chiara
    Parisi, Francesca
    Razeti, Maria Grazia
    Arecco, Luca
    Cosso, Maurizio
    Fregatti, Piero
    Del Mastro, Lucia
    Poggio, Francesca
    Lambertini, Matteo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 241 - 250
  • [22] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
    Quang Anh Le
    Bae, Yuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
    Ponde, Noam
    Ameye, Lieveke
    Lambertini, Matteo
    Paesmans, Marianne
    Piccart, Martine
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 65 - 73
  • [24] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
  • [25] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    William Jacot
    Elvire Pons
    Jean-Sébastien Frenel
    Séverine Guiu
    Christelle Levy
    Pierre Etienne Heudel
    Thomas Bachelot
    Véronique D’Hondt
    Amélie Darlix
    Nelly Firmin
    Gilles Romieu
    Simon Thezenas
    Florence Dalenc
    Breast Cancer Research and Treatment, 2016, 157 : 307 - 318
  • [26] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
    Neelima Denduluri
    Janet L. Espirito
    Michelle D. Hackshaw
    Chuck Wentworth
    Tamy Recchia
    Winghan J. Kwong
    Drugs - Real World Outcomes, 2023, 10 : 177 - 186
  • [27] Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients
    Kowalczyk, Lidia
    Bartsch, Rupert
    Singer, Christian F.
    Farr, Alex
    BREAST CARE, 2017, 12 (06) : 401 - 408
  • [28] PHASE I STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PATIENTS WITH NORMAL OR REDUCED HEPATIC FUNCTION.
    Agarwal, P.
    Li, C.
    Gibiansky, L.
    Dent, S.
    Goncalves, A.
    Nijem, I.
    Strasak, A.
    Lorusso, P.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S21 - S21
  • [29] Trastuzumab emtansine (T-DM1) + capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer (mGC): Results from the phase I/randomized phase II TRAXHER2 study
    Cortes, Javier
    Dieras, Veronique
    Lorenzen, Sylvie
    Montemurro, Filippo
    Riera-Knorrenschild, Jorge
    Thuss-Patience, Peter
    Allegrini, Giacomo
    De laurentiis, Michele
    Lichinitser, Mikhail
    Lohrisch, Caroline
    Perez-Garcia, Jose
    Ricci, Francesco
    Sakaeva, Dina
    Serpanchy, Rosanne
    Sufliarsky, Jozef
    Vidal, Maria
    Irahara, Natsumi
    Wohlfarth, Christine
    Aout, Mounir
    Gelmon, Karen
    CANCER RESEARCH, 2018, 78 (13)
  • [30] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
    Denduluri, Neelima
    Espirito, Janet L.
    Hackshaw, Michelle D.
    Wentworth, Chuck
    Recchia, Tamy
    Kwong, Winghan J.
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 177 - 186
12345